Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics Inc. (Nasdaq: CMPX) advances novel antibody therapies targeting cancer's complex biology through its clinical-stage pipeline. This dedicated news center provides investors and researchers with essential updates on oncology developments, trial milestones, and scientific breakthroughs.
Access timely reports on bispecific antibody programs, including Tovecimig (CTX-009) for biliary tract cancers and CTX-471's CD137 agonist mechanism. Track regulatory progress across multiple indications and discover partnership announcements leveraging Compass' StitchMabs platform technology.
Our curated news collection serves as your primary source for:
- Phase 1-3 clinical trial updates
- FDA submissions and international regulatory milestones
- Peer-reviewed research publications
- Strategic collaborations in immuno-oncology
Bookmark this page for real-time insights into Compass' work on angiogenesis modulation and tumor microenvironment targeting. Monitor biomarker-driven developments that could shape next-generation cancer treatments.
Compass Therapeutics (Nasdaq: CMPX) has announced two significant developments in its biliary tract cancer (BTC) program:
1. Completed enrollment of 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel alone in previously treated, unresectable advanced metastatic or recurrent BTC.
2. Approved an Investigator Sponsored Trial (IST) to study CTX-009 in the first-line setting for BTC patients at The University of Texas MD Anderson Cancer Center. This trial will add CTX-009 to the standard first-line regimen of gemcitabine, cisplatin, and durvalumab.
These developments mark significant progress in Compass Therapeutics' oncology-focused antibody-based therapeutics program, potentially expanding treatment options for BTC patients.
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 5-6, 2024.
The chat is scheduled for June 5 at 1:00-1:25 PM ET and will be webcast live. The presentation will be archived for 90 days on the company's events page.
Compass Therapeutics (Nasdaq: CMPX) has announced a leadership change effective May 28, 2024. Thomas Schuetz, M.D., Ph.D., has been appointed President and CEO, succeeding Vered Bisker-Leib, Ph.D., M.B.A., who stepped down but will continue as a Senior Consultant for 15 months. Dr. Schuetz, previously President of Research and Development and Vice Chair of the Board, expressed enthusiasm about his return to the CEO role and the progress of the company's clinical programs. The Board of Directors thanked Dr. Bisker-Leib for her contributions and wished her well in future endeavors.
Compass Therapeutics announced Phase 1 data for CTX-471, a novel CD137 agonist antibody, demonstrating anti-tumor activity in patients who progressed on PD-1 or PD-L1 inhibitors. The data will be presented at the ASCO Annual Meeting 2024. Five clinical responses were observed, including a complete response in a patient with small-cell lung cancer and partial responses in patients with melanoma and mesothelioma. CTX-471 was well tolerated, with the main dose-limiting toxicity being thrombocytopenia, which resolved. A low incidence of liver toxicity and mostly low-grade adverse events were reported. The study involved 19 patients in the dose escalation phase and 60 in the dose expansion phase.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place in New York City on May 20, 2024, with a fireside chat scheduled for 11:30 AM ET. A webcast of the chat will be available live and archived for 90 days on the company's events page. Compass Therapeutics specializes in developing antibody-based therapeutics aimed at treating various human diseases.
Compass Therapeutics, Inc. (Nasdaq: CMPX) reported their first quarter 2024 financial results and provided a business update. They received FDA Fast Track Designation for CTX-009 for the treatment of biliary tract tumors. Enrollment is progressing well in their clinical trials. They ended the quarter with $156 million in cash and marketable securities, extending their cash runway into late 2026.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
